Outsmarting cancer immunosuppression

Faron Pharmaceuticals’ antibody drug candidate that targets the macrophage receptor Clever-1 may be a game changer in immuno-oncology.

Mar 13, 2019
Page of

Faron Pharmaceuticals

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

No comments yet.